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ABSTRACT
We have previously shown that proto-oncoprotein c-Jun is activated in 
ornithine decarboxylase (ODC)- and RAS-transformed mouse fibroblasts, and that 
the transformed morphology of these cells can be reversed by expressing the 
transactivation domain deletion mutant of c-Jun (TAM67). Here, we found that lysyl 
oxidase (Lox), encoding an extracellular matrix-modifying enzyme, is downregulated 
in a c-Jun-dependent manner in ODC-transformed fibroblasts (Odc cells). In addition 
to Lox, the Lox family members Lox-like 1 and 3 (Loxl1 and Loxl3) were found to 
be downregulated in Odc as well as in RAS-transformed fibroblasts (E4), whereas 
Lox-like 4 (Loxl4) was upregulated in Odc and downregulated in E4 cells compared 
to normal N1 fibroblasts. Tetracycline-regulatable LOX re-expression in Odc cells led 
to inhibition of cell growth and invasion in three-dimensional Matrigel in an activity-
independent manner. On the contrary, LOX and especially LOXL2, LOXL3, and LOXL4 
were found to be upregulated in several human melanoma cell lines, and LOX inhibitor 
B-aminopropionitrile inhibited the invasive growth of these cells particularly when 
co-cultured with fibroblasts in Matrigel. Knocking down the expression of LOX and 
especially LOXL2 in melanoma cells almost completely abrogated the invasive growth 
capability. Further, LOXL2 was significantly upregulated in clinical human primary 
melanomas compared to benign nevi, and high expression of LOXL2 in primary 
melanomas was associated with formation of metastases and shorter survival of 
patients. Thus, our studies reveal that inactive pro-LOX (together with Lox propeptide) 
functions as a tumor suppressor in ODC- and RAS-transformed murine fibroblasts by 
inhibiting cell growth and invasion, and active LOX and LOXL2 as tumor promoters in 
human melanoma cells by promoting their invasive growth.   
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INTRODUCTION
Proto-oncoprotein c-Jun is a transcription factor, a 
member of the AP-1 (activation protein-1) transcription 
factor family. It can dimerize through its leucine zipper 
motif with other members of the AP-1 family (reviewed in 
[1]). c-Jun is involved in many cellular activities, such as 
cell proliferation [2, 3], apoptosis [4], differentiation [5, 6], 
tumor invasion [7, 8], metastasis [9], and angiogenesis 
[10, 11]. c-Jun expression and activity have been found 
to be elevated in cell lines transformed by many different 
oncoproteins, such as receptor tyrosine kinases, Src, Ras, 
Raf, Fos, and Myc [12, 13], and in human cancers, such as 
pancreatic cancer [14], breast cancer [15], sarcomas [16], 
glioblastoma [17], and melanoma [18, 19].
Ornithine decarboxylase (ODC) is a key regulatory 
enzyme in the biosynthesis of polyamines. Like c-Jun, also 
ODC is essential for mammalian development and tumor 
formation [20]. In our earlier studies, we have shown that 
the overexpression of human ODC induces morphological 
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transformation of immortalized NIH3T3 cells [21] and 
gives rise to rapidly growing fibrosarcomas in nude 
mice [22]. ODC-induced transformation was associated 
with constitutive c-Jun activation [23], and induced 
expression of the transactivation domain deletion mutant 
of c-Jun (TAM67) was found to reverse the transformed 
morphology and reduce their invasive growth [24]. Similar 
results were obtained with RAS-transformed mouse 
fibroblasts (E4 cells) [24].
Lysyl oxidase (LOX) is a secreted copper-dependent 
amine oxidase that plays an important role especially in 
the crosslinking of collagen and elastin in the extracellular 
matrix [25]. LOX is synthesized and secreted as a 50-kDa 
inactive glycosylated proenzyme (pro-LOX), which is then 
cleaved extracellularly into a functional 32-kDa enzyme 
(LOX) and an 18-kDa propeptide (LOX-PP) by bone 
morphogenetic protein 1 (BMP-1) and related proteases 
(Tolloid-like 1 and 2) [26]. LOX-PP can further exist in 
differentially glycosylated forms of higher molecular 
weight up to 35 kDa [27]. LOX has been reported 
to control cell phenotype and regulate many cellular 
processes, including cell adhesion, migration, and invasion 
[28–31], as well as epithelial-mesenchymal transition in 
hypoxic conditions [32, 33]. Paradoxically, LOX has 
been reported to function both as a tumor suppressor and 
a promoter in human cancer cells, depending on tumor 
type and stage of progression. Originally, Lox (first named 
the ras recision gene, rrg) was proposed to be a tumor 
suppressor gene when it was found to suppress HRAS-
induced transformation in mouse cells [34, 35]. LOX 
has also been found to function as a tumor suppressor in 
basal and squamous cell carcinoma, gastric cancer, and 
osteosarcoma cells [36–38], but as a tumor promoter in 
colorectal cancer, esophageal squamous cell carcinoma, 
lung adenocarcinoma, and laryngeal cancer [39–42]. 
In addition to LOX, four other LOX family members 
designated as LOX-like proteins LOXL1-LOXL4 have 
been identified in mammals. LOX and LOXL proteins 
contain a conserved C-terminal domain, required for 
the amine oxidase activity, and differing N-terminal 
sequences, which may confer individual functions [43]. 
LOX and LOXL proteins are expressed in different 
developmental states and in different tissues, and they 
seem to be unable to functionally compensate each other. 
Like LOX, also LOX-like proteins may function as tumor 
suppressors [44] or promoters [45–47].
In the present study, we first sought to identify 
c-Jun- and transformation- specific genes downregulated 
in the ODC-transformed fibroblasts (Odc cells) by 
genome-wide microarray analysis. We found that one of 
the genes downregulated by c-Jun in Odc cells is Lox. We 
further studied the significance of it in the ODC-induced 
transformation by generating cell lines with inducible 
LOX (pro-LOX) expression. In addition to Lox, expression 
levels of the other Lox family members, Lox-like-1-4, were 
also studied in these cells and in the RAS-transformed (E4) 
cells. As we had earlier incidentally noticed by microarray 
analysis two melanoma cell lines to overexpress LOXL2 
[48], we additionally studied the expression levels of all 
LOX family genes in different melanoma cell lines. In 
contrast to that in ODC-transformed fibroblasts, we found 
a general increase in the expression of the LOX family 
members in melanoma cells. To resolve this paradox, we 
further studied the functions of the encoded proteins by 
using a universal LOX inhibitor Β-aminopropionitrile 
(BAPN) and knocking down of LOX and LOXL2 in 
melanoma cells. Our data suggest that inactive pro-LOX 
functions as a tumor suppressor in ODC- and RAS-
transformed mouse fibroblasts by inhibiting cell growth 
and invasion, and that the mature, active LOX and LOXL2 
act as tumor promoters in human melanoma cells by 
promoting their invasive growth. Further, we show that 
high LOXL2 mRNA expression may be correlated with 
metastasis and poor survival in melanoma.   
RESULTS
LOX expression is downregulated in ODC-
transformed mouse fibroblasts in a c-Jun-
regulated manner
In this study, we first set out to identify ODC-
induced transformation-associated genes downregulated by 
c-Jun. By using gene expression microarray analyses, we 
searched for genes that are both downregulated in ODC-
transformed cells (Odc cells) compared to parental N1 
fibroblasts as well as upregulated in Odc cells transfected 
with a tetracycline-inducible TAM67 vector (Odc-pLRT-
TAM67) after induction of TAM67 expression. Using two 
different microarray platforms, only three genes - fibulin 
5 (Fbln5), Lox, and microfibrillar associated protein 5 
(Mfap5) (all encoding extracellular matrix proteins) - 
showed ≥ 2-fold changes in their expression levels in the 
two comparisons (Table 1). As Lox has been proposed to 
be a tumor suppressor and also to be downregulated in 
HRAS-transformed mouse cells [34, 35], we selected it to 
be studied in more detail. First, we verified by RT-PCR the 
downregulation of Lox in Odc cells, and the upregulation 
of Lox in Odc-pLRT-TAM67 cells, after TAM67 induction 
(Figure 1A and 1B). We further studied the expression 
of Lox in the RAS-transformed (E4) cells and found its 
expression to be downregulated compared to N1 cells 
(Figure 1A), consistent with previous findings [34, 35]. 
The downregulation of Lox expression in Odc cells was 
also seen at the protein level. Immunoblotting with a LOX 
antibody recognizing both pro-LOX and mature LOX 
revealed that the normal N1 cells contained high levels 
of pro-LOX but no detectable amounts of cleaved/mature 
LOX, and that the transformed Odc cells showed a marked 
decrease in pro-LOX expression (Figure 1C). Analysis of 
the secreted proteins from the cells with the same antibody 
showed that pro-LOX was secreted and cleaved to mature/
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active LOX, roughly proportionally to the cellular levels of 
pro-LOX (Figure 1D and 1E). The cellular protein levels of 
the LOX-propeptide region, detected by LOX-PP antibody 
(Figure 1F, left panel), showed no clear difference between 
the N1 and Odc cells. However, when analyzing the secreted 
proteins, a 26 kDa protein band was detected in N1 cells, 
but not in Odc cells (Figure 1F, right panel). The 26 kDa 
band may well represent glycosylated LOX propeptide [49]. 
The 18 kDa protein band seen in the cell extracts equally 
expressed in the N1 and Odc cells (Figure 1F, left panel) 
is unlikely to be LOX-PP, but represents a protein non-
specifically binding the antibody in NIH3T3 cells [50]. 
Table 1: Identification of genes downregulated in ODC-transformed NIH3T3 cells (Odc) compared to parental N1 
cells and upregulated in Odc cells expressing a tetracycline-inducible TAM67 vector (Odc-pLRT-TAM67) by Incyte 











+dox vs  
–dox
AA437518 Fibulin 5 (Fbln5) –5.5 4.4 –8.8 3
W83882 Lysyl oxidase (Lox) –3.3 2.5 –3.4 2.2
AA037995 Microfibrillar associated protein 5 (Mfap5) –24.2 2.1 –14 2
Values are fold changes.
+dox = with 1 µg/ml doxycycline for 3 days.
–dox = without doxycycline for 3 days.
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Lox and Lox-like 1 and 3 are downregulated in 
Odc and E4 cells
In addition to Lox, we also studied the expression of 
other Lox family members, Lox-like 1-4, in parental N1 
fibroblasts and in ODC- and RAS-transformed (E4) cells 
by Affymetrix microarrays (Table 2). Of the Lox family 
members, the highest expression levels in the cells were 
seen with Lox. Besides Lox, we found Loxl1, and Loxl3 
to be downregulated both in Odc and E4 cells compared 
to normal N1 cells (Table 2). Loxl4 in turn was slightly 
upregulated in Odc cells but downregulated in E4 cells. 
The expression levels of Lox, Loxl1, Loxl3, and Loxl4 
were further verified by RT-PCR (Figure 1A).  Loxl2 was 
not expressed to any appreciable extent in any of these 
cell lines (Figure 1A), in agreement with the microarray 
data (Table 2).
Noteworthy, we also found ODC-transformed 
cells to downregulate, in addition to Lox, the expression 
of many other extracellular matrix (ECM)-related genes 
compared to the parental NIH3T3 fibroblasts, including 
Col1a1 4.1-fold, Col1a2 2.0-fold, and Fn1 10.6-fold. Of 
the downregulated genes 7.4% (56/759) encoded ECM 
proteins, whereas only 0.7% (7/1076) of the upregulated 
genes were ECM-related (data not shown).
Re-expression of pro-LOX inhibits the growth 
and invasion of Odc cells  
To study the functional significance of LOX, we 
generated cell lines carrying a tetracycline-inducible 
expression system of LOX cDNA (pro-LOX) in ODC-
transformed cells (Odc-pLRT-LOX). Cell clones with 
a robust LOX mRNA expression by doxycycline 
induction and low background expression in the absence 
of doxycycline (Figure 2A) were then selected for more 
detailed studies. The induction of LOX expression was 
also confirmed at the protein level (Figure 2B). The 
induced pro-LOX was further verified to be secreted and 
correctly processed to mature LOX by analysis of the 
secreted proteins (Figure 2C). Silver staining showed that 
doxycycline did not affect total protein levels (Figure 2D). 
Analysis of the cellular proteins with the LOX propeptide 
antibody showed an increase in pro-LOX expression 
Figure 1: Expression levels of Lox and Lox-like1-4 in normal (N1), ODC-transformed (Odc), and Ras-transformed 
(E4) mouse fibroblasts. (A) Lox and Loxl1-4 mRNA levels in N1, Odc, and E4 cell lines analyzed by RT-PCR. (B) RT-PCR analysis of 
Lox mRNA expression levels in ODC-transformed fibroblasts transfected with inducible pLRT-TAM67 vector (Odc-pLRT-TAM67 cells) 
in the absence (–dox) and presence (+dox) of 1 µg/ml doxycycline. Gapdh was used as a control. (C) Western blot analysis of cellular 
(40 μg protein/lane) pro-Lox and Lox protein levels in N1 and Odc cell lines and (D) secreted Lox protein levels in N1, Odc, and E4 
cell lines (17 μg protein/lane). (E) Silver staining of total secreted proteins in samples used in (D). (F) Western blot analysis of cellular 
(40 μg protein/lane) and secreted (17 μg protein/lane) pro-Lox and LOX-PP proteins in N1 and Odc cells detected with a LOX propeptide-
specific antibody.
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upon doxycycline induction, but no clear difference could 
be detected in the protein levels of the LOX-PP region 
between the non-induced and induced states (Figure 
2E, left panel). Immunoblotting of the secreted proteins 
with the LOX-PP antibody revealed also an increase in 
pro-LOX, but not in LOX-PP, upon induction of the cells 
with doxycycline (Figure 2E, right panel). Apparently, the 
amount of LOX-PP among the secreted proteins was too 
low to be detected with the antibody. 
Then, we tested the effect of pro-LOX expression 
on the growth rate of Odc cells and found the induced 
expression of pro-LOX to significantly inhibit (p = 0.0014) 
the growth of Odc-pLRT-LOX cells (Figure 3A). Empty 
vector-bearing cells showed no change in growth after 
doxycycline induction (data not shown).
To test whether Lox is also involved in the 
regulation of cell invasion, we used a 3D-Matrigel assay 
mimicking the situation in vivo. The induced expression 
of pro-LOX resulted in a marked inhibition of the 
invasive growth of Odc-pLRT-LOX cells (Figure 3B). 
Doxycycline had no effect on the invasive growth pattern 
of Odc cells with empty control vector (data not shown). 
Next, to study whether the extracellular processing of 
pro-LOX to active LOX enzyme/ the enzyme activity had 
any role in the inhibition of invasion, we incubated the 
cells with BAPN, a competitive, irreversible, active-site 
directed inhibitor of LOX [51], in the absence or presence 
of doxycycline. Although the IC50 value of BAPN for 
different LOX substrates is in the micromolar range 
(1–15 µM) [51–53], higher concentrations of 250 to 500 µM 
BAPN were required to fully block the LOX activity 
in the conditioned medium of the cells (Supplementary 
Figure 1A), consistent with previous findings on other 
cell lines [52, 53]. At these concentrations, BAPN is still 
known to be sufficiently specific to LOX [54]. Further, 
the other possible BAPN-targetable amine oxidases, like 
AOC1 (diamine oxidase) and AOC3 (VAP-1/SSAO), are 
not appreciably expressed in the cell lines studied here 
(data not shown), adding to the specificity of BAPN 
action. The inhibitor at a 500 µM concentration did not 
either show any toxicity, as evidenced by no interference 
with the proliferation of Odc cells in 2D cell culture 
(Supplementary Figure 2) or the invasive activity of the 
cells in 3D-Matrigel (Figure 3C). Thus, the doxycycline-
induced expression of pro-LOX blocked the invasive 
capability of the cells irrespective of LOX activity.
LOX family members are variably expressed in 
different human melanoma cell lines 
In addition to that in fibroblast transformation, we 
have incidentally noticed in our microarray analyses of 
two melanoma cell lines that the expression levels of LOX 
family members change during the development of human 
melanoma cells [48]. As LOXL2 was one of the most 
highly upregulated genes in melanoma cells compared to 
normal melanocytes [48], we were interested to investigate 
the role of all LOX family members in melanoma cells. 
First, we studied the mRNA expression levels of LOX and 
LOXL1-4 in a panel of melanoma cell lines and primary 
melanoma cells, as well as in primary human melanocytes, 
fibroblasts, and endothelial cells. Interestingly, LOXL2 
and LOXL3 were found to be expressed in nearly all 
the melanoma cell lines studied (Figure 4A). LOX was 
expressed at the level of assay sensitivity only in the 
vertical growth phase melanoma cell line WM793 and in 
the metastatic cell lines BLM and SK-MEL-147. LOXL1, 
in turn, was expressed only in BLM and SK-MEL-147 
cell lines, and LOXL4 in the vertical growth phase cell 
line WM115 and in the metastatic cell lines WM239 
and MM170. The primary melanocytes 42V, Mela-3, 
and Mela-TN45 did not express any of the LOX family 
members (Figure 4A and 4B). Human embryonic skin 
fibroblasts (HES), in turn, expressed nearly all the mRNAs 
(except LOXL4), while the endothelial cells (HMVECs) 
expressed only LOXL2 (Figure 4B). Two non-embryonic 
cultures of human primary fibroblasts expressed all 
LOX family members at high levels (Figure 4B). The 
cellular and secreted protein levels of LOX and LOXL2 
in fibroblasts (HES) and melanoma cells (SK-MEL-147, 
WM793 and WM239) were then studied (Figure 5). Pro-
LOX exhibited high expression in HES and lower variable 
Table 2: The gene expression levels of Lox family members in normal (N1), ODC-transformed (Odc), and Ras-
transformed (E4) NIH 3T3 cells analyzed by Affymetrix MOE430 set arrays
Probeset Id Gene
Signal Fold
N1 Odc E4 Odc vs N1 E4 vs N1
1416121_at Lysyl oxidase (Lox) 7849 2223 1268 –3.6 –6.3
1448228_at Lysyl oxidase (Lox) 7385 2167 1070 –3.4 –7.1
1451978_at Lysyl oxidase-like 1 (Loxl1) 2270 696 575 –3.2 –4.0
1418269_at Lysyl oxidase-like 3 (Loxl3) 1033 207 399 –5.0 –2.6
1421153_at Lysyl oxidase-like 4 (Loxl4) 311 539 157 1.7 –2.0
1450134_at Lysyl oxidase-like 4 (Loxl4) 320 481 156 1.5 –3.1
Note: lysyl oxidase-like 2 (Loxl2) expression was absent in all the cell lines.
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expression in melanoma cells, with WM793 showing the 
highest expression among them (Figure 5A). The protein 
expression of LOXL2, in turn, was abundant in both 
HES and the melanoma cells, and varied less than that of 
LOX, with SK-MEL-147 showing the lowest expression 
(Figure 5B). Analysis of the secreted proteins showed 
that pro-LOX was efficiently processed to the active 
LOX, particularly in HES cells, while LOXL2 remained 
unprocessed (Figure 5C).
In addition to cell lines, we also compared the mRNA 
expression levels of LOX and LOXL1-4 in clinical tissue 
specimens of human benign nevi and malignant melanomas, 
and found LOXL1 (fold 1.6; p = 0.0028) and LOXL2 (fold 
2.0; p = 0.00016) to be significantly upregulated in the 
primary melanomas (Figure 6A). In addition, LOXL2 
mRNA expression levels were significantly upregulated 
(fold 2.0; p = 0.0012) in the metastatic compared to non-
metastatic primary melanomas (Figure 6B). Further, we 
compared the Kaplan–Meier survival curves of patients with 
primary melanomas displaying low and high expression of 
LOXL2 and found a significant association between high 
expression of LOXL2 and shorter survival time (Figure 6C).
Figure 2: Ectopic expression of LOX in Odc cells by using tetracycline-inducible system. (A and B) LOX mRNA and 
protein expression levels in the Odc-pLRT-LOX clones in the absence (–dox) and presence (+dox) of doxycycline, as analyzed by Northern 
blotting (10 μg RNA/lane) (A) and Western blotting (40 μg protein/lane) (B). Actin was used as a loading control in Northern blotting 
(A) and α-tubulin in Western blotting (B). (C) Analysis of the secreted LOX protein levels (17 μg protein/lane) as analyzed by Western 
blotting. (D) Silver staining of total secreted proteins in samples used in (C). (E) Western blot analysis of cellular (40 μg protein/lane) and 
secreted (17 μg protein/lane) pro-LOX and LOX-PP proteins with LOX-PP antibody in Odc-pLRT-LOX cells, without or with induction 
of lysyl oxidase expression. 
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Figure 4: Expression of LOX family members in different human normal cells, primary melanoma cells, and melanoma 
cell lines. (A) Expression of LOX and LOXL1-4 mRNAs in normal melanocytes (42V) and a panel of melanoma cell lines, and (B) in 
human embryonic fibroblasts (HES), human microvascular endothelial cells (HMVECs), normal melanocytes (Mela-TN45 and Mela3), 
primary melanoma cells (EL29), and in WM793 and WM239 melanoma cell lines, as well as in primary fibroblasts, as analyzed by RT-
PCR. Beta-actin (ACTB) was used as a loading control.
Figure 3: Effect of ectopic LOX expression on cell growth and invasion of ODC-transformed fibroblasts transfected 
with a tetracycline-inducible expression system (Odc-pLRT-LOX). (A) Growth curves of Odc-pLRT-LOX cells grown for 
5 days in the absence (–dox) or presence (+dox) of doxycycline. Data are expressed as means ± SD of three parallel cultures. *p = 0.0014 
at 5 days of culture. (B) Odc-pLRT-LOX cells grown between two thick layers of Matrigel in the absence or presence of doxycycline and 
photographed after 3 days. (C) Odc-pLRT-LOX cells grown in Matrigel without (–dox and –dox+BAPN) or with (+dox and +dox+BAPN) 
doxycycline and with LOX inhibitor ΒAPN (500 µM) (–dox+BAPN and +dox+BAPN) and photographed after 2 days.
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Inhibition of LOX activity suppresses the 
invasive growth of human melanoma cells and 
fibroblasts
To study the effects of LOX family members on 
melanoma cell behavior, we first inhibited LOX activity in 
WM793 cells with 250 and 500 µM BAPN, which effectively 
blocked the enzyme activity in vitro (Supplementary Figure 
1B), and studied cell proliferation in standard 2D culture. 
BAPN at these concentrations did not interfere with cell 
growth, when cultured at ordinary cell densities (Figure 
7A). However, a minor, non-significant (p = 0.12) decrease 
in the proliferation rate was detected in sparse cell cultures 
(Supplementary Figure 3). We further checked that BAPN 
did not induce apoptosis in WM793 and SK-MEL-147 
cells at these concentrations (data not shown). By contrast, 
BAPN (500 µM) completely abrogated the low invasive 
activity of WM793 cells, and partially inhibited the high 
invasive capability of SK-MEL-147 cells in 3D Matrigel 
(Figure 7B and 7C). Notably, when the melanoma cells 
were co-cultured in 3D Matrigel with fibroblasts (which 
we have found to dramatically promote the invasion of 
melanoma cells [55]), inhibition of LOX activity led to a 
complete inhibition of the co-invasive growth of fibroblasts 
and melanoma cells (both WM793 and SK-MEL-147 cells; 
WM793 already with 250 µM BAPN) (Figures 8 and 9). 
We further used fluorescent labeling of melanoma cells 
(red) and fibroblasts (green) to differentiate the effect of 
Figure 5: Protein expression levels of LOX and LOXL2 in human fibroblasts and melanoma cell lines. (A and B) Western 
blot analysis of cellular pro-LOX (A) and LOXL2 (B) protein levels in human embryonic fibroblasts (HES), and melanoma cell lines SK-
MEL-147, WM793, and WM239. Actin and alpha-tubulin were used as the loading controls. (C) Western blot analysis of secreted LOX 
and LOXL2 protein levels in HES cells, and melanoma cell lines SK-MEL-147, WM793, and WM239.
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LOX inhibition on the two cell types in the co-cultures 
(Figures 8 and 9). In the absence of the inhibitor, fibroblasts 
became spindle shaped/activated and came into direct 
contact with the melanoma cells, as we have previously 
reported [55]. Inhibition of LOX activity blocked the 
activation of fibroblasts (cells remained round) and 
inhibited the subsequent growth and invasion of both cell 
types (Figures 8 and 9). 
Knockdown of LOX and LOXL2 inhibit the 
proliferation and invasive growth of WM793 
melanoma cells
Finally, we examined the functional consequences 
of the depletion of LOX and LOXL2 proteins by specific 
short-hairpin RNAs (shRNAs) in WM793 cells. We found 
that the proliferative capacity of the cells in standard 2D 
Figure 6: Expression of LOX and LOX-like genes in clinical human melanoma samples. (A) Comparison of the mean 
mRNA expression levels of LOX and LOX-like genes in benign nevi and primary melanomas. (B) Comparison of the mean mRNA 
expression levels of LOXL2 in primary melanomas with and without metastases. The relative mRNA levels were measured by Affymetrix 
HG U133 Plus 2.0 arrays. Error bars indicate SDs. (C) Kaplan–Meier survival curves for melanoma patient groups with primary melanoma 
showing low and high LOXL2 mRNA expression measured by Affymetrix HG U133 Plus 2.0 and HG U133 set arrays.
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Figure 7: Effects of LOX inhibitor β-aminopropionitrile (BAPN) on the proliferation and invasive growth of melanoma 
cells. (A) The cell numbers of WM793 melanoma cells grown for 3 and 5 days in the presence of 0, 250, or 500 µM ΒAPN. 104 cells were 
initially plated. (B and C) WM793 (B) and SK-MEL-147 (C) melanoma cells cultured in 3D Matrigel without or with BAPN at 250 or 500 µM 
concentrations; 3 × 104 WM793 and 2 × 104 SK-MEL-147 melanoma cells were plated between the two layers of Matrigel; WM793 was 
cultured for 4 days and SK-MEL-147 for 3 days.
Figure 8: Effect of LOX inhibitor BAPN on the invasive growth of co-cultured WM793 melanoma cells and human 
embryonic fibroblasts (HES). Fluorescent-labeled WM793 cells (104) (red) (B, F, J) and fibroblasts (104) (green) (C, G, K) co-cultured 
in 3D Matrigel without (A–D) and with BAPN at 250 (E–H) or 500 (I–L) µM concentrations for 24 hours. D: merged image of B and C; 
H: merged image of F and G; L: merged image of J and K.
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culture was markedly reduced (Figure 10A), and that 
the invasive growth capacity in 3D Matrigel was almost 
totally inhibited (Figure 10B) after knocking down LOX 
(Figure 10C). The depletion of LOXL2 with two different 
shRNAs (TRCN0000046195 and TRCN0000046197) 
(Figure 10D and 10E) resulted in even more extensive 
reduction in cell proliferation than that of LOX in 2D 
culture (Figure 10A), and the invasive growth capability of 
the cells in 3D Matrigel was completely blocked during the 
follow-up for three days (Figure 10B and data not shown). 
As the antiproliferative effect of the knockdowns results 
in counter selection of the high shRNA expressing cells 
during an extended culture, inducible shRNA expression 
models should preferably be developed for future studies.
DISCUSSION
LOX family members have been proposed to play 
multiple, complex roles in cancer, functioning both as 
tumor suppressors and metastasis promoters. Here, we 
show Lox to be downregulated in ODC-transformed 
mouse NIH3T3 fibroblasts in a c-Jun-dependent manner 
and to inhibit the proliferation and invasive growth of 
these cells. Also other members of the Lox gene family, 
Loxl1 and Loxl3, were downregulated in Odc cells. We 
have previously demonstrated that ODC is a downstream 
effector of mutant HRAS-induced transformation in 
NIH3T3 cells [56, 57]. In cells that have been transformed 
by the RAS oncogene or genes signaling through RAS, the 
tumor suppressive action of LOX has mostly been linked 
to LOX-PP, which is extracellularly cleaved from pro-LOX 
and then uptaken by the cells [49, 58–61]. In these studies, 
LOX-PP has been found to reduce cell proliferation and 
migration in vitro and tumor formation in vivo, through 
inhibiting Akt, MAPK, and NFκB activation. In addition, 
LOX-PP has been reported to have extracellular sites of 
action [62, 63]. In our study, we could not detect LOX-
PP in the cellular extracts of normal NIH3T3 cells 
(N1), which contained only pro-LOX, consistent with a 
previous study by Contente et al. [50]. In the analysis of 
secreted proteins from N1 cells, we detected pro-LOX, 
mature LOX, and LOX-PP (a 26-kDa band, apparently 
representing glycosylated LOX-PP), in line with the 
known secretion and cleavage of pro-LOX [26]. Further, 
in an inducible LOX expression model in Odc cells, we 
did not either detect any appreciable increases in LOX-
PP in the cellular extracts, nor in the secreted proteins. 
Apparently the secreted levels of LOX-PP were too low 
to be detected immunologically with the current system. 
However, the transformed phenotype of the cells was 
reverted to normal upon induction of LOX expression. The 
morphological reversion was further found to occur in the 
presence of the inhibitor of LOX activity, BAPN. All these 
data together suggest that under physiological conditions 
pro-LOX, and not LOX-PP, is the main tumor suppressor 
in NIH3T3 cells. This conclusion is also supported by the 
findings of Contente et al. [50] on normal and HRAS-
transformed NIH3T3 cells. However, the latter study did 
not include analyses of secreted proteins, and the authors 
also appear to have expressed LOX cDNA without the 
signal sequence, in which case the protein is not normally 
secreted. It is clear, however, that also LOX-PP has tumor 
Figure 9: Effect of LOX inhibitor BAPN on the invasive growth of co-cultured SK-MEL-147 melanoma cells and HES 
cells. Fluorescent-labeled SK-MEL-147 (red) (B, F, J) and fibroblasts (green) (C, G, K) co-cultured (1:1) in 3D Matrigel without (A–D) 
or with BAPN at 250 (E–H) or 500 (I–L) µM concentrations for 24 hours. D: merged image of B and C; H: merged image of F and G; L: 
merged image of J and K.
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suppressive functions, and several lines of evidence show 
that LOX-PP may be a good pharmacological agent to be 
used in cancer therapy [64].
The tumor- and metastasis-promoting function of 
LOX, in turn, has been linked in many studies to the lysyl 
oxidase enzyme activity, which is typically increased in 
cancer cells under hypoxic (low oxygen) conditions [65]. 
Inhibition of LOX activity by BAPN has been found to 
inhibit invasion and migration of tumor cells in vitro and 
to reduce metastasis formation in vivo [31, 65, 66], but 
no or only a marginal inhibition of cell proliferation by 
BAPN in standard 2D cultures has usually been observed 
[29, 58].  However, depending on the culture conditions, 
LOX activity has also been found to be needed for cell 
proliferation [53, 67, 68]. As a competitive inhibitor, the 
effects of BAPN may also be affected by the concentrations 
of the different substrates of LOX produced by different 
cell types. Here, we found that inhibition of LOX activity 
by BAPN had only a minimal, if any, effect on the 
proliferation of melanoma cells in 2D culture, but markedly 
inhibited the invasive growth of the cells in 3D Matrigel, 
particularly when co-cultured with fibroblasts. Notably, 
BAPN has also been reported to inhibit the activity of 
other LOX family members [69, 70], of which LOXL2 and 
LOXL3 were found to be expressed by both melanoma 
cells and fibroblasts, making the interpretation of the 
results complicated. To assess the specific roles played by 
the individual LOX family members, specific inhibitors, 
chemical compounds or antibody inhibitors, such as 
AB0023 for LOXL2 [70] would be needed. A couple 
of new, non-commercially available pharmacological 
inhibitors for LOX family members have recently been 
introduced [53, 71, 72], but the development of highly 
specific inhibitors is hampered by the fact that the crystal 
structures of the LOX family proteins are not yet resolved. 
Interestingly, our studies revealed that the depletion of 
LOX, and particularly that of LOXL2 by shRNAs inhibited 
both the proliferative capacity and the invasive growth 
capability of melanoma cells much more effectively than 
BAPN. Thus, the development of the enzyme activity-
based inhibitors alone may not be sufficient, but we 
may have to invent various means to interfere with the 
expression or functions (including protein interactions) of 
the LOX family members to effectively combat cancer. 
Besides the cancer cell intrinsic factors, tumor 
progression also depends on other cells. We have 
previously shown that the interaction between melanoma 
cells and fibroblasts, and their invasive growth in co-
cultures in Matrigel is driven by TGFbeta [55], which 
also can induce the expression of all members of the 
Figure 10: Effects of LOX- and LOXL2- knockdowns on the proliferation and invasive growth of WM793 melanoma 
cells. (A) The proliferation of WM793 melanoma cells 10 days after the lentiviral transduction of control, LOX, LOXL2a (clone 
TRCN0000046195) and LOXL2b (clone TRCN0000046197) shRNAs. Data are expressed as means ± SD of three parallel cultures. 
p < 0.001 in all (control shRNA versus LOX, LOXL2a or LOXL2b shRNAs). (B) WM793 melanoma cells cultured in 3D Matrigel 3 weeks 
after the transduction with lentiviral control, LOX, or LOXL2a (clone TRCN0000046195) shRNAs. The cells were photographed after 
1 and 2 days. (C and D) Western blot analysis of LOX (C) and LOXL2 (D) protein levels in the conditioned media of WM793 cells. The 
cells transduced in duplicates with lentiviral control and LOX shRNAs (C) and control and LOXL2 (clone TRCN0000046195) shRNAs 
(D) were passaged for 32 days in normal serum containing media and changed to serum free medium for 18 hours before collecting the 
conditioned media. (E) Silver staining of total secreted proteins in samples used in (C and D).
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LOX family [73]. In breast cancer cells, endogenous 
LOX and LOXL2 expression has been shown to be 
upregulated when the cells were incubated with 
fibroblast-conditioned medium or plated on a fibroblast-
conditioned collagen matrix [74]. Also reciprocally, 
LOXL2 secreted by cancer cells has been shown to 
activate fibroblasts and increase LOXL2 production in 
the fibroblasts [75]. Thus, co-culturing of melanoma 
cells and fibroblasts together may activate a feed-
forward loop leading to increased expression of many 
LOX family proteins in both cell types. Hence, further 
studies are needed to clarify the specific roles of 
the different LOX proteins in the collaborating cells 
regulating melanoma cell behavior.
The function of LOX as a tumor suppressor versus 
promoter may thus depend, besides its processing and 
activity, on the cell type, stage of progression, cellular 
contexts, and the mode of cell migration/invasion. 
Interestingly, we found ODC-transformed fibroblasts 
to downregulate, in addition to Lox, the expression of 
many other ECM-related genes compared to parental 
NIH3T3 fibroblasts, including those encoding collagen I 
and fibronectin. As a consequence of this, the collagen I 
content and its crosslinking (and the deposition of fibrillar 
ECM in general) are reduced in the ODC-transformed 
cells compared to normal NIH3T3 cells (N1). We have 
previously shown that the N1 cells do not form tumors 
(or only form tiny tumors), while the ODC-transformed 
cells produce rapidly growing and locally invasive tumors 
in nude mice [22]. Hence, the formation of collagen I 
and its crosslinking in normal NIH3T3 cells is associated 
with tumor suppression. By contrast, we have found 
that melanoma tumors, like many other tumors, show 
upregulated expression of ECM-related genes, which 
may be expressed by both melanoma cells and stromal 
cells [76, 77 and this study]. Here, we found that also 
the expression of LOX, LOXL1, and LOXL3 encoding 
proteins that crosslink ECM proteins (collagens and 
elastin) are increased in many melanoma cells and primary 
melanomas. Consequently, melanoma development and 
progression is associated with an increase in fibrillar 
network of ECM proteins (like collagen I, fibronectin, and 
periostin) around the melanoma cells [76]. Interestingly, 
fibronectin and periostin are also known to activate LOX 
[78, 79]. We have speculated that the tubular meshwork 
structures formed by these ECM proteins (together 
with matrix proteases) provide specific channels for 
melanoma tumor cells to invade and spread [76, 80]. 
In fact, many solid tumor cells have been suggested to 
use aligned crosslinked collagen bundles to migrate and 
invade [81]. However, a recent study in a pancreatic 
cancer model represents a caution that depletion of 
cancer-associated (αSMA+) fibroblasts and fibrosis may, 
surprisingly, accelerate pancreas cancer with reduced 
survival. Nonetheless, the expression of LOX appeared 
to remain high [82]. One explanation to this may be that 
during evolution (or artificial genetic manipulation) some 
cancer cells may gain independence of fibroblasts [76], or 
that other types of cancer-associated fibroblasts or other 
stromal cells compensate for the reduction in αSMA+ 
fibroblast functions.
Stromal or tumor cell-derived LOX expression 
has also been reported to play an important role in 
angiogenesis and tumor metastasis [83, 84]. Further, 
LOXL2 expression both in cancer cells and associated 
stromal fibroblasts has been shown to correlate with 
metastasis and poor survival in gastric cancer [85]. 
LOXL2 may also serve as a prognostic factor in melanoma 
as we found high LOXL2 mRNA expression in primary 
melanomas to be associated with formation of metastases 
and shorter survival of patients. These results remain 
interesting to be validated in a larger data set. Likewise, 
high LOXL2 mRNA expression has been found to 
associate with lymph node metastasis in esophageal 
squamous cell carcinoma [86] and with decreased overall 
survival in lung squamous cell carcinoma and lymph 
node-negative breast adenocarcinoma [87], and in colon 
cancer [88]. In addition, high LOXL2 protein expression 
has been found to associate with poorer overall survival 
in gastric cancer [89], laryngeal squamous cell carcinoma 
[87], and breast cancer [90].
In conclusion, in a search for genes involved in 
cell transformation, we found by microarray and RT-
PCR analyses Lox, Loxl1, and Loxl3 downregulation 
in ODC- and RAS-transformed mouse fibroblasts 
compared to normal fibroblasts, and upregulation of Lox 
in Odc-pLRT-TAM67 cells, upon induction of TAM67 
expression. Induced re-expression of LOX in Odc-pLRT-
LOX cells led to inhibition of cell growth and invasion 
in 3D Matrigel in an activity-independent manner. Our 
data thus suggest that the inactive pro-LOX acts as major 
tumor suppressor, in addition to the previously known 
LOX-PP. It will be interesting to see whether various 
possible means to increase the extracellular content of 
pro-LOX, e.g. by inhibiting the cleavage of pro-LOX 
with BMP1 inhibitors or with competitive pro-LOX-
specific cleavage site peptides, would offer a viable 
strategy to inhibit tumor progression. Conversely, we 
found upregulation of LOX and other LOXL family 
members, especially LOXL2 and LOXL3, in several 
human melanoma cell lines. LOXL2 proved to be the 
most interesting among the LOX family members in 
melanomas, as it was significantly upregulated in clinical 
human melanomas compared to benign nevi, and it was 
associated with the formation of metastases and shorter 
survival of patients. We further show that the invasive 
growth of melanoma cells can be inhibited with ΒAPN, 
and even totally blocked by depletion of LOX and 
LOXL2 with shRNAs. Altogether, therapeutic targeting 
of the LOX family members, especially LOX and 
LOXL2, by promoting the tumor suppressive function of 
LOX and/or inhibiting the activity or expression of these 
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enzymes, may offer viable ways to combat melanoma 
and other cancers.      
MATERIALS AND METHODS 
Patient samples
Fresh benign nevi from healthy volunteers and 
primary cutaneous melanomas (Breslow’s thickness 
0.6–27 mm) were obtained by surgical excision at 
Helsinki University Central Hospital, Helsinki, Finland, 
and processed as described previously [55, 77, 91]. 
Adjacent sections were subjected to pathological and 
immunohistochemical examinations. The protocols 
for taking the specimens were approved by the Ethics 
Committees of the Helsinki University Central Hospital. 
Further, all patients gave their informed consent.
Cell culture
NIH3T3 mouse fibroblasts stably transfected with 
the human ODC cDNA (Odc; [21]) and the HRASVal12 
(c-Ha-rasVal12) oncogene (E4; [57]) were cultured in 
DMEM or α-MEM  (both from Invitrogen/Thermo 
Fischer Scientific, Carlsbad, CA, USA) containing 
penicillin, streptomycin, and 5% fetal bovine serum 
(FBS; Invitrogen). NIH3T3 cells transfected only with the 
neomycin resistance gene (N1) were used as a control.
Odc cells stably transfected with a tetracycline-
inducible expression system of the transactivation domain 
deletion mutant of c-Jun (pLRT-TAM67) [24] or lysyl 
oxidase (pLRT-LOX) were grown in α-MEM containing 
50 μg/ml gentamicin (Invitrogen) and 5% TET system 
approved FBS (Clontech, Laboratories Inc., Mountain 
View, CA, USA). 
Primary human melanocytes were isolated and 
cultured as previously described [76, 80, 92]. The 
melanoma cell lines WM793 (established from a vertical 
growth phase melanoma) and WM239 (established from 
a melanoma metastasis) were kindly provided by Dr. 
Meenhard Herlyn (Wistar Institute, Philadelphia, PA, 
USA). The vertical growth phase melanoma cell line 
WM115 and the metastatic cell line SK-MEL-28 were from 
ATCC-LCG Standards (Borås, Sweden). The metastatic 
melanoma cell lines SK-MEL-103 and SK-MEL-147 were 
kindly provided by Dr. Marisol Soengas (Spanish National 
Cancer Research Centre, Madrid, Spain), and MM170 cell 
line was from CellBank Australia (Westmead, Australia). 
WM793, WM115, WM239, MM170, and SK-MEL-28 
melanoma cell lines were cultured in RPMI 1640 (Sigma-
Aldrich, St. Louis, MO, USA) containing 10% FBS and 
antibiotics. SK-MEL-103, SK-MEL-147, and BLM were 
grown in DMEM containing 10% FBS and antibiotics 
[77]. Human primary embryonic skin fibroblasts (HES) 
and melanoma cells isolated from a primary tumor 
(EL29) were grown in RPMI 1640 containing 10% FBS 
and antibiotics. Human microvascular endothelial cells 
(HMVECs; Invitrogen) were grown in growth factor-
supplemented Medium 131 (Invitrogen).    
Generation of NIH 3T3 cell lines carrying a 
tetracycline-inducible expression system of lysyl 
oxidase (pLRT-LOX)
Human LOX cDNA (HLO20 fragment; [93]) was 
first cloned into pBluescript and then inserted in XhoI/
NotI-digested reverse tetracycline-regulated retroviral 
vector pLRT. The pLRT-LOX plasmid or empty 
vector were stably transfected into Odc cells by using 
Lipofectamine PLUS or Lipofectamine 2000 (Invitrogen). 
Selection of transfected cells was started after two days 
with 5 μg/ml blasticidin (Invitrogen) and continued 
for 1–2 weeks. After that, the stable transfectants were 
maintained in 1 μg/ml blasticidin. Several clones were first 
picked up by cylinder cloning and subcloned by single-cell 
cloning in 96-wells. The LOX expression was induced by 
1 μg/ml doxycycline (Sigma-Aldrich) and the clones were 
analyzed by Northern blotting, reverse transcription-PCR 
(RT-PCR), and Western blotting. The best clones were 
selected for further studies.
Short hairpin RNA lentiviral particle 
transduction of melanoma cells
WM793 cells were grown to 60% confluency and 
transduced with MISSION® shRNA Lentiviral Transduction 
Particles (Sigma-Aldrich) targeting LOX (SHCLNV-
NM_002317; clone TRCN0000045991), LOXL2 
(SHCLNV-NM_002318; clones TRCN0000046195 and 
TRCN0000046197) or with MISSION® Non-Mammalian 
shRNA Control Transduction Particles (SHC002V) in 
the presence of 8 μg/ml polybrene. Transductions were 
performed in duplicates in 96-well plates according to the 
manufacturer’s instructions, except using 1 × 104 cells for 
transfections.  
Fluorescent labeling of living cells
Living melanoma cells and fibroblasts were labeled 
with Fluorescent Celltracker Dyes before experiments as 
previously described [55]. Celltracker Green CMFDA 
was used for fibroblasts and Celltracker Red CMTPX 
(Molecular Probes/Invitrogen) for melanoma cells. 
Analysis of cell growth
To study the effect of LOX re-expression on cell 
growth, we used Odc cells carrying the tetracycline-
inducible pLRT-LOX or empty vector. The cells were 
plated in triplicates in the absence or presence of 
doxycycline (1 μg/ml) and the total numbers of cells 
were counted with a Coulter particle counter (Beckman 
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Coulter, Fullerton, CA, USA) after 3 and 5 days (medium 
changed after 3 days). To study the effect of ΒAPN on cell 
growth of Odc and WM793 cells, the cells were cultured 
in triplicates with 0, 250, or 500 µM BAPN and counted 
after 3 and 5 days. The medium and ΒAPN were changed 
after 3 days. In addition, the cell numbers of WM793 
cells transduced with control shRNA, LOX shRNA, or 
two different LOXL2 shRNAs were counted 10 days 
after transduction with the shRNA lentiviral transduction 
particles.
Analysis of apoptosis and cell death
Apoptosis and cell death were analyzed by using 
CellEvent™ Caspase-3/7 Green ReadyProbes™ Reagent 
and ReadyProbes™ Cell Viability Imaging kit, Blue/Red 
(Invitrogen by Thermo Fisher Scientific). 
Matrigel invasion assays
Growth factor-reduced Matrigel (BD Biosciences, 
Franklin Lakes, NJ) was used in 3D invasion assays 
essentially as previously described [24, 94]. Briefly, 1 × 104 
Odc-pLRT-LOX cells (pretreated or not with 1 μg/ml 
doxycycline for 1–3 days), 2 to 3 × 104 melanoma cells, or 
1 × 104 melanoma cells mixed with 1 × 104 HES cells (in 
co-culture assays; [55]) were seeded onto 24-well plates 
pre-coated with 300 µl of Matrigel diluted 1:3 in serum-free 
growth medium. Cells were allowed to adhere for 1 hour, 
after which a second 250-µl layer of Matrigel solution was 
added and allowed to polymerize. Finally, 500 μl of growth 
medium containing 5 to 10% serum was added to cover the 
Matrigel. The Matrigel layers and the growth medium were 
supplemented or not with 1 μg/ml doxycycline, and with or 
without the irreversible LOX inhibitor BAPN (0, 250, or 500 
µM), [51]. The patterns of cell growth were monitored daily 
by microscopy and photographed after 1 to 4 days by using 
Olympus IX71 microscope and Olympus DP70 camera 
(both from Tokyo, Japan) [24, 55, 94, 95].
RNA extraction
Polyadenylated mRNA for Northern blot analysis 
and cDNA LifeArrays was extracted by oligo(dT) 
cellulose chromatography [57]. Total RNA for RT-PCR 
and Affymetrix microarray analyses was isolated with 
the RNeasy kit (Qiagen, Crawley, UK) according to 
manufacturer’s instructions.
Northern blot analysis
LOX mRNA levels of the tetracycline-inducible 
LOX derivatives of Odc cells were confirmed by Northern 
blot analysis as previously described [95]. The single-
stranded LOX antisense RNA probe was generated from 
the HLO20 sense fragment.
Microarray analyses
Polyadenylated RNAs were extracted from the 
cells and analyzed with Mouse GEM2/Unigene1 cDNA 
LifeArrays (Incyte Genomics, Palo Alto, CA, USA), as 
previously described [95, 96]. Total RNA was extracted 
from the cells and hybridized to Affymetrix oligonucleotide 
MOE430 Set arrays, as previously described [95, 96]. 
Human benign nevi and primary melanomas were analyzed 
with HG-U133 Plus 2.0 Array (Affymetrix, Santa Clara, 
CA, USA), as previously described [91].
Reverse transcription-PCR analysis
The expression levels of LOX and LOXL1-4 were 
analyzed by RT-PCR essentially as previously described 
[95]. One μg of total RNA was used to synthesize cDNA, 
of which 1/10 (v/v) was subjected to PCR amplification. 
The mouse and human specific primers designed (from 
Proligo, Paris, France) and PCR variables are listed 
in Supplementary Tables 1 and 2, respectively. The 
primers for mouse Loxl1 and Loxl3 have previously 
been published in [79]. Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) was used as a control with mouse 
cells and β-actin (ACTB) with human cells. The primers 
and PCR conditions for Gapdh and ACTB were the same 
as previously described [91, 95], except that the number of 
cycles for Gapdh was 20 and for ACTB 25. PCR products 
were separated on 2% agarose gels and visualized with 
Gel Star Nucleic Acid Gel Stain (Cambrex Bio Science 
Rockland, Rockland, ME, USA) under UV light. Gel Doc 
2000 and Quantity One 4.2.3 software (Bio-Rad, Hercules, 
CA, USA) were used in gel documentation.
Western blot analysis
Secreted proteins were first concentrated using 
Amicon Ultra Cel-10 centrifugal filters (MWCO 10.000; 
Millipore, Bedford, MA, USA) as previously described 
[94]. Cellular lysates or secreted proteins were resolved by 
10% SDS-PAGE, and the proteins were electrophoretically 
transferred onto nitrocellulose membrane (Bio-Rad, 
Herwles, Hercules, CA, USA) and analyzed as previously 
[24]. Secreted and cellular protein bands of human 
melanoma cells and fibroblasts were quantified using 
Image Studio Lite (LI-COR Biotechnology, Lincoln, 
NE, USA). A rabbit polyclonal antibody recognizing the 
C-terminal domain of LOX (L4669; Sigma-Aldrich), a 
rabbit polyclonal LOX propeptide antibody to LOX-PP 
(NB110-41568; Novus Biologicals, Littleton, CO, USA), 
and a rabbit polyclonal antibody to LOXL2 (ab96233; 
Abcam, Cambridge, UK) were used to detect the 
respective proteins. Secreted protein samples were verified 
to contain comparable amounts of total proteins by silver 
staining. Mouse monoclonal antibodies to alpha-tubulin 
(DM1A; Abcam) and actin (JLA20; Merck, Millipore, 
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Billerica, MA, USA) were used as loading controls for 
cellular proteins. 
Fluorimetric lysyl oxidase assay
Amplite™ Fluorimetric Lysyl Oxidase Assay Kit 
(ATT Bioquest®, Inc., Sunnyvale, CA, USA) was used to 
detect the activity of lysyl oxidase in the media of N1 and 
WM793 cells. After growing for two days in normal serum 
containing media the cells were washed and transferred to 
serum free media for 18 h. The conditioned media were 
collected, and secreted proteins were concentrated using 
Amicon Ultra Cel-10 centrifugal filters (MWCO 10.000; 
Millipore, Bedford, MA, USA), as previously described 
[94]. The lysyl oxidase activity in the concentrated media 
was measured in the presence of 0, 250, or 500 µM ΒAPN 
and 0.1% albumin. Recombinant LOXL2, rhLOXL2 (Bio-
techne Ltd, Abingdon, UK), was used as a positive control.
Statistical analysis
Data analyses were performed using a two-tailed 
Welch’s t-test, where p < 0.05 was considered statistically 
significant. The Kaplan–Meier survival curves were 
compared with the use of log-rank test in SPSS 21.0 
software (SPSS, Chicago, USA).
Abbreviations
ODC: ornithine decarboxylase; LOX: lysyl 
oxidase; LOXL: lysyl oxidase-like; LOX-PP: lysyl 
oxidase propeptide; BAPN: B-aminopropionitrile; ECM: 
extracellular matrix.
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